233 related articles for article (PubMed ID: 33476575)
41. Fas apoptosis inhibitory molecule is upregulated by IGF-1 signaling and modulates Akt activation and IRF4 expression in multiple myeloma.
Huo J; Xu S; Lin B; Chng WJ; Lam KP
Leukemia; 2013 Apr; 27(5):1165-71. PubMed ID: 23138182
[TBL] [Abstract][Full Text] [Related]
42. Preclinical activity of CPI-0610, a novel small-molecule bromodomain and extra-terminal protein inhibitor in the therapy of multiple myeloma.
Siu KT; Ramachandran J; Yee AJ; Eda H; Santo L; Panaroni C; Mertz JA; Sims Iii RJ; Cooper MR; Raje N
Leukemia; 2017 Aug; 31(8):1760-1769. PubMed ID: 27890933
[TBL] [Abstract][Full Text] [Related]
43. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells.
Derenne S; Monia B; Dean NM; Taylor JK; Rapp MJ; Harousseau JL; Bataille R; Amiot M
Blood; 2002 Jul; 100(1):194-9. PubMed ID: 12070027
[TBL] [Abstract][Full Text] [Related]
44. Targeting both BET and CBP/EP300 proteins with the novel dual inhibitors NEO2734 and NEO1132 leads to anti-tumor activity in multiple myeloma.
Ryan KR; Giles F; Morgan GJ
Eur J Haematol; 2021 Jan; 106(1):90-99. PubMed ID: 32997383
[TBL] [Abstract][Full Text] [Related]
45. An IRF4-MYC-mTORC1 Integrated Pathway Controls Cell Growth and the Proliferative Capacity of Activated B Cells during B Cell Differentiation In Vivo.
Patterson DG; Kania AK; Price MJ; Rose JR; Scharer CD; Boss JM
J Immunol; 2021 Oct; 207(7):1798-1811. PubMed ID: 34470852
[TBL] [Abstract][Full Text] [Related]
46. The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in
Díaz T; Rodríguez V; Lozano E; Mena MP; Calderón M; Rosiñol L; Martínez A; Tovar N; Pérez-Galán P; Bladé J; Roué G; de Larrea CF
Haematologica; 2017 Oct; 102(10):1776-1784. PubMed ID: 28751557
[TBL] [Abstract][Full Text] [Related]
47. Interferon regulatory factor 4 (IRF4) is overexpressed in human non‑small cell lung cancer (NSCLC) and activates the Notch signaling pathway.
Qian Y; Du Z; Xing Y; Zhou T; Chen T; Shi M
Mol Med Rep; 2017 Nov; 16(5):6034-6040. PubMed ID: 28849037
[TBL] [Abstract][Full Text] [Related]
48. Interferon Regulatory Factor 4 Inhibits Neointima Formation by Engaging Krüppel-Like Factor 4 Signaling.
Cheng WL; She ZG; Qin JJ; Guo JH; Gong FH; Zhang P; Fang C; Tian S; Zhu XY; Gong J; Wang ZH; Huang Z; Li H
Circulation; 2017 Oct; 136(15):1412-1433. PubMed ID: 28851732
[TBL] [Abstract][Full Text] [Related]
49. Interferon regulatory factors 4 and 8 induce the expression of Ikaros and Aiolos to down-regulate pre-B-cell receptor and promote cell-cycle withdrawal in pre-B-cell development.
Ma S; Pathak S; Trinh L; Lu R
Blood; 2008 Feb; 111(3):1396-403. PubMed ID: 17971486
[TBL] [Abstract][Full Text] [Related]
50. Quantitation of multiple myeloma oncogene 1/interferon-regulatory factor 4 gene expression in malignant B-cell proliferations and normal leukocytes.
Yamada M; Asanuma K; Kobayashi D; Moriai R; Yajima T; Yagihashi A; Yamamori S; Watanabe N
Anticancer Res; 2001; 21(1B):633-8. PubMed ID: 11299818
[TBL] [Abstract][Full Text] [Related]
51. Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression.
Zhang LH; Kosek J; Wang M; Heise C; Schafer PH; Chopra R
Br J Haematol; 2013 Feb; 160(4):487-502. PubMed ID: 23252516
[TBL] [Abstract][Full Text] [Related]
52. EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.
Alzrigat M; Párraga AA; Agarwal P; Zureigat H; Österborg A; Nahi H; Ma A; Jin J; Nilsson K; Öberg F; Kalushkova A; Jernberg-Wiklund H
Oncotarget; 2017 Feb; 8(6):10213-10224. PubMed ID: 28052011
[TBL] [Abstract][Full Text] [Related]
53. UTX/KDM6A Loss Enhances the Malignant Phenotype of Multiple Myeloma and Sensitizes Cells to EZH2 inhibition.
Ezponda T; Dupéré-Richer D; Will CM; Small EC; Varghese N; Patel T; Nabet B; Popovic R; Oyer J; Bulic M; Zheng Y; Huang X; Shah MY; Maji S; Riva A; Occhionorelli M; Tonon G; Kelleher N; Keats J; Licht JD
Cell Rep; 2017 Oct; 21(3):628-640. PubMed ID: 29045832
[TBL] [Abstract][Full Text] [Related]
54. Essential role of interferon regulatory factor 4 (IRF4) in immune cell development.
Nam S; Lim JS
Arch Pharm Res; 2016 Nov; 39(11):1548-1555. PubMed ID: 27826752
[TBL] [Abstract][Full Text] [Related]
55. IFN regulatory factor 4 and 8 promote Ig light chain kappa locus activation in pre-B cell development.
Ma S; Turetsky A; Trinh L; Lu R
J Immunol; 2006 Dec; 177(11):7898-904. PubMed ID: 17114461
[TBL] [Abstract][Full Text] [Related]
56. IFN Regulatory Factor 4 Controls Post-ischemic Inflammation and Prevents Chronic Kidney Disease.
Lorenz G; Moschovaki-Filippidou F; Würf V; Metzger P; Steiger S; Batz F; Carbajo-Lozoya J; Koziel J; Schnurr M; Cohen CD; Schmaderer C; Anders HJ; Lindenmeyer M; Lech M
Front Immunol; 2019; 10():2162. PubMed ID: 31632388
[TBL] [Abstract][Full Text] [Related]
57. Targeting MYC in multiple myeloma.
Jovanović KK; Roche-Lestienne C; Ghobrial IM; Facon T; Quesnel B; Manier S
Leukemia; 2018 Jun; 32(6):1295-1306. PubMed ID: 29467490
[TBL] [Abstract][Full Text] [Related]
58. IRF4 is a suppressor of c-Myc induced B cell leukemia.
Pathak S; Ma S; Trinh L; Eudy J; Wagner KU; Joshi SS; Lu R
PLoS One; 2011; 6(7):e22628. PubMed ID: 21818355
[TBL] [Abstract][Full Text] [Related]
59. Shared and distinct functions of the transcription factors IRF4 and IRF8 in myeloid cell development.
Yamamoto M; Kato T; Hotta C; Nishiyama A; Kurotaki D; Yoshinari M; Takami M; Ichino M; Nakazawa M; Matsuyama T; Kamijo R; Kitagawa S; Ozato K; Tamura T
PLoS One; 2011; 6(10):e25812. PubMed ID: 22003407
[TBL] [Abstract][Full Text] [Related]
60. MUM1/IRF4: A Review.
Gualco G; Weiss LM; Bacchi CE
Appl Immunohistochem Mol Morphol; 2010 Jul; 18(4):301-10. PubMed ID: 20182347
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
